Ra Pharmaceuticals
Ra Pharma is developing Cyclomimetics™, a new drug class combining the properties and benefits of antibodies and small molecules.
Launch date
Employees
Market cap
-
Enterprise valuation
$2.3b (Public information from Oct 2019)
Cambridge Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $10.3m | Early VC | |
| N/A | $8.6m | Series A | |
$58.5m | Series B | ||
| N/A | €91.6m Valuation: €263m | IPO | |
* | $2.3b Valuation: $2.3b | Acquisition | |
| Total Funding | $77.4m | ||
Related Content
Recent News about Ra Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.